Midsized Pharma Partnerships And AI Tools Will Streamline Operations

Published
08 Aug 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$218.47
18.3% undervalued intrinsic discount
14 Aug
US$178.56
Loading
1Y
-45.0%
7D
11.8%

Author's Valuation

US$218.5

18.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Increased 2.54%

Shared on30 Apr 25
Fair value Increased 1.37%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 1.82%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Decreased 10%

AnalystConsensusTarget has decreased revenue growth from 4.2% to 3.7%.

Shared on09 Apr 25
Fair value Increased 35%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 28%

Shared on26 Mar 25
Fair value Decreased 1.18%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 40%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Decreased 0.20%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.